Alcresta Therapeutics Inc., a commercial-stage company focused on developing and commercializing novel, enzyme-based products, announced on Monday that it has named Chris Parrish as its chief operations officer effective 29 November 2021.

Parrish has over 25 years of experience in the biotechnology and medical device industry. He has served as the vice president of Manufacturing at Vericel Corporation. He has also supported product launches and the commercial success of various cell therapy products. He started his career with Pfizer as a scientist in research and development and quality.

Daniel Orlando, Alcresta Therapeutics Inc CEO, said, 'Alcresta's rapid growth requires an experienced, dynamic operations leader to sustain current commercial demand while guiding launch preparations for our near-term pipeline. Chris has demonstrated operational success in rare disease, built and led high performance quality, manufacturing, and operations cross-functional teams, and, most importantly, consistently delivered life-changing therapeutics to patients in critical need.'